The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Abstract
One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Expanded Disability Status Scale (EDSS [26]) was administered by an experienced neurologist (M.C.) to investigate physical disability.”
From Coping strategies and their impact on quality of life and physical disability of people with multiple sclerosis (2021) · cites this paper as [26]
Citations
Cites
On the evaluation of disability in multiple sclerosis
Kurtzke, J. F. (1961) · Neurology · doi:10.1212/wnl.11.8.686 · Cited by 330
Further notes on disability evaluation in multiple sclerosis, with scale modifications
Kurtzke, J. F. (1965) · Neurology · doi:10.1212/wnl.15.7.654 · Cited by 309
A New Scale for Evaluating Disability in Multiple Sclerosis
Kurtzke, J. F. (1955) · Neurology · doi:10.1212/wnl.5.8.580 · Cited by 305
Wood, P. (1980) · PubMed · Cited by 247
NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE
Kurtzke, J. F. (1970) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1970.tb05808.x · Cited by 156
A PROPOSAL FOR A UNIFORM MINIMAL RECORD OF DISABILITY IN MULTIPLE SCLEROSIS
Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05548.x · Cited by 127
Kurtzke, J. F., Beebe, G. W., Nagler, B., Auth, T. L., Kurland, L. T., & Nefzger, M. D. (1972) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1972.tb07525.x · Cited by 68
Mellerup, E., Fog, T., Raun, N. E., Colville, P., de Rham, B., Hannah, B., & Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05549.x · Cited by 53
The effects of isoniazid on patients with multiple sclerosis; preliminary report.
Kurtzke, J. F., & Berlin, L. (1954) · PubMed · doi:10.1164/art.1954.70.4.577 · Cited by 23
ACUTE RESPIRATORY FAILURE IN MULTIPLE SCLEROSIS AND ITS MANAGEMENT
Guthrie, T. C., Kurtzke, J. F., & BERLIN, L. (1952) · Annals of Internal Medicine · doi:10.7326/0003-4819-37-6-1197 · Cited by 20
Cited by
Sorted by citations
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdová, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., LUBLIN, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,433
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E. W., O'Connor, P. W., Polman, C. H., Hohlfeld, R., Calabresi, P. A., Selmaj, K. W., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,670
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comı, G., Hartung, H., Khatri, B. O., Montalbán, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,220
Metadata
- Authors
- Kurtzke, J. F.
- Affiliations
- Georgetown University (US)
- Corresponding author
- Kurtzke, John F.
- Venue
- Neurology
- Published
- 1983-11
- Volume
- 33
- Issue
- 11
- Pages
- 1444-1444
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2112165124
- Cited by
- 15,011
- References
- 13
- Citations by year
- 2026: 474 · 2025: 622 · 2024: 692 · 2023: 648 · 2022: 722 · 2021: 781 · 2020: 764 · 2019: 648 · 2018: 603 · 2017: 592 · 2016: 657 · 2015: 634 · 2014: 632 · 2013: 586 · 2012: 581
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Health Professions › Speech and Hearing › Voice and Speech Disorders
- Keywords
- multiple sclerosis, Expanded Disability Status Scale, disability assessment, neurological deficit, functional systems, pyramidal system, cerebellar function, brainstem, sensory impairment, bowel and bladder dysfunction, visual impairment
- MeSH terms
- Humans, Multiple Sclerosis, Nervous System Diseases, Neurologic Examination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review